Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andrew James

Clinical Nurse Specialist, Medical-Surgical Columbia, MO Clinical Nurse Specialist

NPI 1871586321 CMS profile 10792719

1 S Keene St, Columbia, MO 65201

Open in the dashboard

General payments

$25,716

115 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$181 paid to institutions, not to them · program year 2021

Through program year 2025, Andrew James of Columbia, MO is reported in the CMS Open Payments database as having received $25,716 across 115 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $181 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Clinical Nurse Specialist, Medical-Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,893 15
2024 General $7,061 37
2023 General $5,641 21
2022 General $7,682 20
2021 General $3,440 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew James
  • Clinical Nurse Specialist, Medical-Surgical median
  • Middle half of Clinical Nurse Specialist, Medical-Surgical
  • National median

In program year 2025, general payments to Andrew James were reported at $1,893. Among 59 Clinical Nurse Specialist, Medical-Surgical profiles paid that year, the median was $165 and the middle half received between $54 and $254.

Show as a table
Year Andrew James Clinical Nurse Specialist, Medical-Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $3,440 $214 $58–$714 $132
2022 $7,682 $153 $29–$560 $149
2023 $5,641 $119 $27–$460 $160
2024 $7,061 $124 $52–$304 $164
2025 $1,893 $165 $54–$254 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $22,565 77 payments
  2. Radius Health, Inc. $2,919 26 payments
  3. Alvogen Inc $73 3 payments
  4. Novo Nordisk Inc $52 3 payments
  5. Kyowa Kirin, Inc. $36 2 payments
  6. Impulse Dynamics (USA) Inc. $21 1 payment
  7. ASCEND Therapeutics US, LLC $20 1 payment
  8. Integra LifeSciences Corporation $16 1 payment
  9. Lilly USA, LLC $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,644 22 payments
  2. Travel and Lodging $6,498 11 payments
  3. Education $2,418 9 payments
  4. Food and Beverage $2,156 73 payments
Products named General payments · program years 2021–2025
  1. EVENITY $16,748 63 payments
  2. Prolia $6,093 35 payments
  3. Tymlos Endocrinology $2,433 17 payments
  4. Tymlos Endocrinology $103 5 payments
  5. TERIPARATIDE $73 3 payments
  6. Crysvita $36 2 payments
  7. Wegovy $33 2 payments
  8. Optimizer Smart System $21 1 payment
  9. BINOSTO $20 1 payment
  10. TCC-EZ $16 1 payment
  11. Other $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

616

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$1,013,937

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

61%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tymlos Abaloparatide Brand 191 $467,466
Teriparatide Generic 53 $194,094
Prolia Denosumab Brand 81 $141,315
Forteo Teriparatide Brand 32 $133,545
Evenity (2 Syringes) Romosozumab-Aqqg Brand 33 $74,625
Ultra-Fine Short Pen Needle Pen Needle, Diabetic Brand 26 $1,507
Alendronate Sodium Generic 170 $938
Unifine Pentips Plus Pen Needle, Diabetic Brand 13 $345
Baclofen Generic 17 $102

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$1,783,993

Of which drugs: $1,696,651

Medicare patients

957

Average age 76

Services billed

121,854

824 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Osteoporosis 75%
High blood pressure 69%
Arthritis 66%
Depression 23%
Ischemic heart disease 20%
Diabetes 19%
Atrial fibrillation 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 575 58,140 $1,177,905
Injection, romosozumab-aqqg, 1 mg J3111 Office 61 60,900 $518,740

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $6,535
$6,535 33 60,900
Tymlos
  • Radius Health, Inc. $298
$298 191 —
Prolia
  • Amgen Inc. $70
$70 81 58,140
TERIPARATIDE
  • Alvogen Inc $48
$48 85 —
Wegovy
  • Novo Nordisk Inc $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Medical-Surgical in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record